Geographic Atrophy Market Report 2024-2034: Promising Product Pipeline, New Product Launches, And Collaborations Bolster Growth

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The "Geographic Atrophy market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering.
Overall world revenue for the Geographic Atrophy Market will surpass US$4.50 billion in 2024

This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Collaborations Among Market Players are Driving the Market Growth
Rising collaborations amongst market players are driving market growth because they combine diverse expertise, resources, and technologies, accelerating the development and commercialisation of innovative treatments. Partnerships allow companies to share risks and costs associated with research and development, access each other's strengths, and enhance their competitive edge.
Challenges Associated with GA Treatment Likely to Hamper Market Growth
Geographic atrophy (GA) treatment faces significant challenges, particularly in remote areas with limited healthcare access, leading to delayed detection and treatment. Raising awareness about eye health and regular exams is crucial. Current GA treatments are hindered by the lack of a cure, limited effectiveness, frequent administration, and inability to reverse damage.

Advanced imaging technologies and genetic research are essential for accurate diagnosis and targeted therapies. Promising treatments, including gene and stem cell therapies, are in development, but the lack of validated endpoints and failures of late-stage drugs underscore the ongoing difficulties in treating GA.
Key Questions Answered

• How is the geographic atrophy market evolving?
• What is driving and restraining the geographic atrophy market?
• How will each geographic atrophy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each geographic atrophy submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading geographic atrophy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the geographic atrophy projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of geographic atrophy projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the geographic atrophy market?
• Where is the geographic atrophy market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, the new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising geographic atrophy prices and recent developments.

Geographic Atrophy Market Dynamics
Market Driving Factors

• New Product Launches is Driving the Market Growth
• Rising Geriatric Population
• Growing Prevalence of Geographic Atrophy

Market Restraining Factors

• High Cost of Novel Drugs is Restraining the Growth of the GA Market
• Challenges Associated with the Geographic Atrophy Treatment

Market Opportunities

• Promising Product Pipeline
• Collaborations Amongst Market Players
• Increase in R&D Investments by Pharmaceutical & Biopharmaceutical Companies

Regulatory Framework

Emerging Markets and Megatrends

Porter's Five Forces Analysis

PEST Analysis

Company Profiles

• Alkeus Pharmaceuticals, Inc.
• Bausch + Lomb
• Ionis Pharmaceuticals
• Santen Pharmaceutical Co., Ltd.
• Astellas Pharma Inc.
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd.
• Apellis Pharmaceuticals
• AstraZeneca
• Johnson & Johnson

Segments Covered in the Report

Type

• Focal GA
• Multifocal GA
• Confluent GA

Drugs

• Pegcetacoplan (SYFOVRE)
• Avacincaptad pegol (IZERVAY)
• Others

Route of Administration

• Intravitreal Route
• Intravenous Route
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce Pharmacies

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Rest of Asia Pacific

Rest of the World (RoW)

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

MENAFN07012025004107003653ID1109063128